Authored By: Sarah
11 Jul 2024

 Hepatitis B Therapeutics Market Size to grow by USD 469.5 million between 2024-2028

According to a research report “ Hepatitis B Therapeutics Market” by Application (Drugs, Vaccines) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 469.5 million, at a CAGR of  3.27% during the forecast period. In the realm of public health, the prevalence and manifestation of Hepatitis B (HBV) infection exhibit significant age-related variations. Infants below the age of 5 and immunosuppressed adults typically exhibit no symptoms, with approximately 90% of infected infants developing chronic infections. Conversely, 30%-50% of individuals older than 5 years present with specific symptoms. Notably, the risk of chronic infection escalates with age at infection. According to the Centers for Disease Control and Prevention (CDC), 90% of infected infants become chronically infected, compared to a mere 2%-6% of adults. Tragically, up to 1 out of 4 of these chronically infected infants succumb to the disease within a short timeframe. Moreover, HBV-infected pregnant women can transmit the virus to their infants at birth, emphasizing the importance of vaccination for newborns to mitigate this risk.

Browse market data tables, figures, and in-depth TOC on “Hepatitis B Therapeutics Market” by Application (Drugs, Vaccines) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Application, the Drugs segment is projected to dominate the market size in 2024

ai_market_segmentation_by

By Geography, North America  segment is expected to hold the largest market size for the year 2024

The Hepatitis B Therapeutics Market is experiencing significant growth, particularly in the drugs segment. This expansion is driven by recent product approvals and groundbreaking technological advancements in hepatitis B treatment. Notably, the escalating research and development (R&D) expenditures by organizations to develop innovative diagnostic tools and identify the stage of liver infection caused by the virus fuel the demand for target-specific drugs. Consequently, the continuous initiatives by industry players and the recent approvals of novel hepatitis B treatments are propelling market growth throughout the forecast period.

North America is forecasted to hold the largest market size by region in 2024

The Hepatitis B therapeutics market represents a significant business opportunity due to the high prevalence of this infectious disease worldwide. Key players in this sector are developing innovative treatments to address the unmet medical needs of patients. Advanced therapies, such as nucleos(t)ide analogs and immunotherapies, are gaining traction, offering improved efficacy and reduced side effects. The market is expected to grow robustly, driven by increasing disease awareness, technological advancements, and expanding patient populations.

The Hepatitis B Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • Biotest AG
  • Bristol Myers Squibb Co.
  • CASI Pharmaceuticals Inc.
  • Cipla Inc.
  • Dynavax Technologies Corp.
  • Emergent BioSolutions Inc.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Hetero Healthcare Ltd.
  • Johnson and Johnson Services Inc.
  • Merck and Co. Inc.
  • Novartis AG
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Hepatitis B therapeutics market encompasses vaccination services for hepatitis B prevention, drugs for treating chronic infections, and diagnostic services for detection and follow-up of the disease. Hepatitis B is a viral liver infection caused by the Hepatitis B virus (HBV), which can lead to chronic diseases such as cirrhosis and hepatocellular carcinoma. Transmission occurs through poor sanitation conditions, infected mothers during childbirth, and contact with infected body fluids, including those from infected needles, infected sexual partners, and illicit drugs. Hepatitis B can also co-exist with hepatitis C, and both viruses can cause liver damage and drug resistance. Diagnosis involves clinical trials, laboratory testing expenses, and biomarker-based testing. Recombinant vaccines are available for newborns and infected mothers to prevent prenatal transmission. Chronic hepatitis B can lead to liver damage and cirrhosis, making early diagnosis and treatment crucial. Drug resistance and co-infection with other factors like alcohol can complicate treatment. The market for Hepatitis B therapeutics is expected to grow due to the increasing burden of chronic diseases and the need for effective treatments.

Market Research Overview

The Hepatitis B and C therapeutics market encompasses the development and commercialization of effective drugs for the treatment and prevention of these deadly liver diseases. Hepatitis B and C are major global health concerns, particularly in areas with unsafe health care and unsafe injections, which are common sources of infection from blood-borne pathogens like the hepatitis B virus (HBV) and hepatitis C virus (HCV). Hepatitis B can lead to chronic infection, prenatal transmission, and even hepatocellular carcinoma, while acute and chronic hepatitis C can cause inflammation, liver damage, and cirrhosis. Effective drugs for hepatitis B include nucleoside analogue therapies, immunosuppressant therapy, and chemotherapy. For hepatitis C, antivirals such as direct-acting antivirals (DAAs) are the primary treatment. Prevention measures include vaccination services, clean syringes, and counseling for medical conditions like alcohol consumption and illicit drug use. Dicerna Pharmaceuticals is a leading player in the hepatitis therapeutics market, developing RNA therapeutics for the treatment of chronic hepatitis B. The burden of these diseases is significant, with an estimated 257 million people living with chronic hepatitis B and C worldwide. Newly infected individuals and chronically infected patients require ongoing follow-up, diagnosis, and treatment, which can be expensive due to laboratory testing and drug resistance. Awareness regarding hepatitis is crucial for prevention, with vaccination services like the 3 antigen HBV vaccine and combination vaccines like HEPLISAV B playing a vital role. Prevention measures also include avoiding risk factors like poor sanitation conditions and unsafe injections. Pharmacy professionals and online, retail, and hospital pharmacies play a critical role in ensuring access to these essential drugs and vaccines. Biomarker-based testing and liver infection screening are also important for early diagnosis and effective treatment.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio